Примери за използване на Ribavirin may на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Ribavirin may cause severe birth defects.
Peginterferon alfa and ribavirin may be continued.
Ribavirin may cause birth defects and/or death of the fetus.
Common side effects with the combination of Pegasys and ribavirin(may affect up to 1 in 10 people) are.
Addition of ribavirin may be considered for genotype 3 infected.
Co-infection with hepatitis C andtreatment with alpha interferon and ribavirin may constitute a special risk.
Ribavirin may cause birth defects and/or death of the exposed foetus.
Uncommon side effects with the combination of Pegasys and ribavirin(may affect up to 1 in 100 people) are.
Ribavirin may be used in combination with interferon alfa-2b(see section 4.4).
Very rarely, PegIntron alone or in combination with ribavirin may cause aplastic anaemia.
Ribavirin may be added based on clinical assessment of an individual patient.
Very common side effects with the combination of Pegasys and ribavirin(may affect more than 1 in 10 people) are.
Ribavirin may be restarted per the dosing modification guidelines for ribavirin. .
Patients co-infected with hepatitis C andtreated with alpha interferon and ribavirin may constitute a special risk.
Addition of Viraferon and ribavirin may increase your risk of lactic acidosis and of liver failure.
Patients co-infected with hepatitis C andtreated with alpha interferon and ribavirin may constitute a special risk.
Addition of ribavirin may be considered for genotype 3 infected patients with compensated cirrhosis(see section 5.1.).
If you are receiving HAART,the addition of Pegasys+ ribavirin may increase your risk of lactic acidosis or liver failure.
Patients with advanced liver disease receiving HAART may be at increased risk of worsening liver function,therefore adding treatment with this medicine alone or in combination with ribavirin may increase their risk.
Adding treatment with alpha interferons alone or in combination with ribavirin may increase the risk in this patient population.
If the abnormality is reversed, ribavirin may be restarted at 600 milligrams daily, and further increased to 800 milligrams daily at the discretion of the treating physician.
Adding treatment with alfa interferons alone or in combination with ribavirin may increase the risk in this patient subset.
Use in patients under the age of 18 years: Ribavirin may be used in combination with interferon alfa-2b in children 3 years of age and older and adolescents.
Adding treatment with an alpha interferon alone or in combination with ribavirin may increase the risk in this patient subset.
From this analysis the only cases that ribavirin may be of benefit is in patients with HCV genotype 1a baseline RAVs.
Combination therapy of Victrelis,peginterferon alfa and ribavirin may influence some patients' ability to drive and use machines.
However, the combination therapy of Victrelis,peginterferon alfa and ribavirin may make you feel tired, faint, a sensation of your head spinning, changes in blood pressure, confused or difficulty seeing clearly.
If you are receiving HAART,the addition of IntronA and ribavirin may increase your risk of lactic acidosis and of liver failure.
If you are an HCV/HIV co-infected adult patient receiving HAART,the addition of this medicine and ribavirin may increase your risk of lactic acidosis, liver failure, and development of blood abnormalities(reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets).
The intended dose of 1.5g/kg of ViraferonPeg to be used in combination with ribavirin may be delivered in weight categories with the ViraferonPeg strengths according to Table 1.